Skip to content
Levomilnacipran
Fetzima (levomilnacipran) is a small molecule pharmaceutical. Levomilnacipran was first approved as Fetzima on 2013-07-25. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent dopamine transporter.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Fetzima (generic drugs available since 2023-01-06)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levomilnacipran hydrochloride
Tradename
Company
Number
Date
Products
FETZIMAAbbVieN-204168 RX2013-07-25
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
fetzimaNew Drug Application2019-10-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
major depressive disorderEFO_0003761D003865F22
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Levomilnacipran Hydrochloride, Fetzima, Abbvie
88659372032-05-23DS, DP
84815982031-03-02U-839
RE438792026-01-11U-839
ATC Codes
N: Nervous system drugs
N06: Psychoanaleptics
N06A: Antidepressants
N06AX: Other antidepressants in atc
N06AX28: Levomilnacipran
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis perennialD012221EFO_1001417J30.8911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RhinitisD012220EFO_0008521J3122
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVOMILNACIPRAN
INNlevomilnacipran
Description
Levomilnacipran (brand name Fetzima) is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN
Identifiers
PDB
CAS-ID96847-54-0
RxCUI1433212
ChEMBL IDCHEMBL99946
ChEBI ID
PubChem CID6917779
DrugBankDB08918
UNII IDUGM0326TXX (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A4
SLC6A4
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 381 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fetzima
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
27 adverse events reported
View more details